Éric Assenat
A5039119608- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Liver Disease Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Genetic factors in colorectal cancer
- Liver physiology and pathology
- Nutrition and Health in Aging
- Cancer Mechanisms and Therapy
- Cancer, Hypoxia, and Metabolism
- Liver Disease and Transplantation
- Gallbladder and Bile Duct Disorders
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Organ Transplantation Techniques and Outcomes
Hôpital Saint Eloi
2016-2025
Université de Montpellier
2014-2025
Institut de Recherche en Cancérologie de Montpellier
2015-2025
Kenya Medical Research Institute
2025
Centre Hospitalier Universitaire de Montpellier
2015-2024
Centre National de la Recherche Scientifique
2012-2024
Institut de Génétique Moléculaire de Montpellier
2012-2024
Hôpital Arnaud de Villeneuve
2024
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2022
Hôpital Avicenne
2021
Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting oxaliplatin, irinotecan, fluorouracil, leucovorin (FOLFIRINOX) as compared with gemcitabine first-line therapy in patients metastatic pancreatic cancer.We randomly assigned 342 an Eastern Cooperative Oncology Group performance status score 0 or 1 (on scale to 5, higher scores indicating greater severity illness) receive FOLFIRINOX (oxaliplatin, 85 mg per square meter body-surface area; 180 meter;...
Among patients with metastatic pancreatic cancer, combination chemotherapy fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy safety of a modified FOLFIRINOX regimen as adjuvant therapy in resected cancer.
Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast receptors implicated in tumorigenesis angiogenesis hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib had been treated sorafenib.In all, 395 advanced progressed on/after were intolerant randomly assigned (2:1)...
<h3>Importance</h3> Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for treatment of advanced hepatocellular carcinoma. <h3>Objective</h3> To assess efficacy everolimus in patients with carcinoma whom sorafenib failed. <h3>Design, Setting, and Participants</h3> EVOLVE-1 was a randomized, double-blind, phase 3 study conducted among 546 adults Barcelona Clinic Liver Cancer stage B or C Child-Pugh A liver function whose disease progressed during after...
No standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether gemcitabine and oxaliplatin chemotherapy (GEMOX) would increase relapse-free survival (RFS) while maintaining health-related quality of life (HRQOL) patients who undergo resection.We performed a multicenter, open-label, randomized phase III trial 33 centers. Patients were randomly assigned (1:1) within 3 months R0 or R1 resection BTC receive...
Circulating tumor cells (CTC) in blood are promising new biomarkers potentially useful for prognostic prediction and monitoring of therapies patients with solid tumors including colon cancer. Moreover, CTC research opens a avenue understanding the biology metastasis However, an in-depth investigation CTCs is hampered by very low number these cells, especially colorectal Thus, establishment cell cultures permanent lines from has become most challenging task over past year. Here, we describe,...
INTRODUCTION: Inhibition of tumor growth factor-β (TGF-β) receptor type I potentiated the activity sorafenib in preclinical models hepatocellular carcinoma (HCC). Galunisertib is a small-molecule selective inhibitor TGF-β1 I, which demonstrated phase 2 trial as second-line HCC treatment. METHODS: The combination galunisertib and (400 mg BID) was tested patients with advanced Child-Pugh A liver function without prior systemic therapy. dose administered 80 or 150 b.i.d. orally for 14 days...
Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment modified FOLFIRINOX vs gemcitabine in patients resected pancreatic ductal adenocarcinoma; mature data are now available.To report 5-year outcomes and explore prognostic factors for overall survival.This open-label, phase was conducted 77 hospitals France Canada included aged 18 to 79 histologically confirmed adenocarcinoma who had undergone...
There is no molecular biomarker available in the clinical practice to assess prognosis of advanced pancreatic carcinoma. This multicenter prospective study aimed investigate role KRAS mutation subtypes within primary tumor determine cancer.The exon-2 status was tested on endoscopic ultrasound-guided fine-needle aspiration biopsy material (primary tumor; restriction fragment-length polymorphism plus sequencing and TaqMan allelic discrimination) patients with proven locally and/or metastatic...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and additional first-line treatments are needed. The programmed cell death protein 1 inhibitor tislelizumab demonstrated efficacy tolerable safety profile as second-line HCC treatment.To investigate vs sorafenib tosylate for treatment unresectable HCC.The open-label, global, multiregional phase 3 RATIONALE-301 randomized clinical trial enrolled systemic therapy-naive adults with histologically confirmed HCC,...
[<sup>177</sup>Lu]Lu-DOTATATE has been approved for progressive and inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that overexpress somatostatin receptors. The absorbed doses by limiting organs can be quantified serial postinfusion scintigraphy measurements of the γ-emissions from <sup>177</sup>Lu. objective this work was to explore how dosimetry could influence clinical management predicting treatment efficacy (tumor shrinkage survival) toxicity. <b>Methods:</b> Patients...
Abstract Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and retrospective study were used determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would associated with dose‐limiting toxicity (DLT) in colon cancer patients. Toxicity over four cycles was graded according NCI Common Criteria V2 or V3 (Common Terminology for Adverse Events, National Cancer Institute, Bethesda, MD). Muscle tissue measured by...
Purpose To determine the diagnostic performance of intravoxel incoherent motion (IVIM) parameters and apparent diffusion coefficient (ADC) to assess response combined chemotherapy radiation therapy (CRT) in patients with rectal cancer by using histogram analysis derived from whole-tumor volumes single-section regions interest (ROIs). Materials Methods The institutional review board approved this retrospective study 31 who underwent magnetic resonance (MR) imaging before after CRT, including...
LBA4001 Background: FOLFIRINOX is more effective than gem as first-line treatment in metastatic pancreatic cancer for patients (pts) with good performance status. This trial assessed the benefit of mFOLFIRINOX adjuvant setting. Methods: PRODIGE 24/CCTG PA.6 a phase III multicenter, randomized clinical trial. Pts aged 18-79 years histologically proven ductal adenocarcinomas, 21-84 days after R0 or R1 resection, WHO PS ≤1, adequate hematologic and renal function, no cardiac ischemia, were...